New Developments in Our Basic Understanding of Tuberculosis

摘要 我们请求支持一个题为《我们的基本知识的新发展》的Keystone研讨会 对结核病的理解，由Samuel M.Behar博士和Valerie Mizrahi博士组织。会议将于 2017年1月14日至18日在加拿大不列颠哥伦比亚省温哥华举行。作为一种传染性疾病，结核病仍然存在 在许多国家和脆弱人群中流行。在这些环境中，这是一个主要原因 发病率和死亡率。在过去的二十年里，人们再次努力开发疫苗。 和新的抗生素。然而，新的发现改变了我们对寄主易感性的理解， 免疫和疾病发病机制还没有跟上临床试验的进展。有必要 可以限制世界各地结核病影响的新方法。本次研讨会将集中讨论 关于宿主-病原体相互作用的基本问题，将致力于 模型系统中的细菌和宿主，以及试图解决人类基本问题的那些 免疫学和疾病。虽然回答这些问题可能不是临床进展的先决条件，但 提高了对结核分枝杆菌生存和颠覆策略的机械性理解 用来逃避治疗和宿主免疫的人将有助于制定更好的治疗和预防策略 肺结核。具体地说，会议的目标是：1)阐明一套优先问题和目标，以 指导该领域的基础研究议程；2)整合领先科学家采用的成功方法 可解决结核病免疫方面的知识差距的其他领域；以及3)突出新的技术 使更复杂的人类实验生物学成为可能的进展，包括定义关键的 需要回答的问题，以加快临床进展。

ABSTRACT Support is requested for a Keystone Symposia meeting entitled New Developments in Our Basic Understanding of Tuberculosis, organized by Drs. Samuel M. Behar and Valerie Mizrahi. The meeting will be held in Vancouver, BC, Canada from January 14-18, 2017. As a contagious disease, tuberculosis remains endemic in many countries and among vulnerable populations. In these settings, it is a major cause of morbidity and mortality. During the past two decades, there has been a renewed effort to develop vaccines and new antibiotics. However, new discoveries that have transformed our understanding of host susceptibility, immunity and disease pathogenesis have not kept pace with the progress of clinical trials. There is a need for new approaches that can limit the impact of tuberculosis around the world. This symposium will focus on fundamental questions about the host-pathogen interaction, bringing together scientists working on the bacterium and the host in model systems, as well as those trying to address basic questions in human immunology and disease. While answering these questions may not be a prerequisite to clinical progress, an improved mechanistic understanding of the survival and subversion strategies that Mycobacterium tuberculosis employs to evade therapy and host immunity will facilitate development of better strategies to treat and prevent tuberculosis. Specifically, the goals of the meeting are to: 1) Articulate a set of priority questions and goals to guide a basic research agenda for the field; 2) Integrate successful approaches employed by leading scientists in other fields that can address knowledge gaps in immunity to tuberculosis; and 3) Highlight new technical advances that make possible more sophisticated human experimental biology including defining the critical questions that need to be answered to expedite clinical advances.